Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase

International Journal of Molecular Sciences

Volumn 16, Issue 4, 2015, Pages 8884-8895

  Falvella, Felicia Stefania ^a   Caporale, Marta ^b   Cheli, Stefania ^a   Martinetti, Antonia ^b   Berenato, Rosa ^b   Maggi, Claudia ^b   Niger, Monica ^b   Ricchini, Francesca ^b   Bossi, Ilaria ^b   Di Bartolomeo, Maria ^b   Sottotetti, Elisa ^b   Bernardi, Francesca Futura ^c   de Braud, Filippo ^b   Clementi, Emilio ^a,d   Pietrantonio, Filippo ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d SCIENTIFIC INSTITUTE   (Italy)

Author keywords

Dihydropyrimidine dehydrogenase; Fluoropyrimidines; Pharmacogenetics; Single nucleotide polymorphisms; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLFIRI; FOLFOX; IRINOTECAN; MICRORNA; MICRORNA 27A; MICRORNA 27B; OXALIPLATIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE;

COLORECTAL CANCER; DIARRHEA; DNA METHYLATION; DNA POLYMORPHISM; ENZYME ACTIVITY; EPIGENETICS; GENE EXPRESSION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; META ANALYSIS (TOPIC); NEUTROPENIA; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREDICTIVE VALUE; REVIEW; SENSITIVITY ANALYSIS; SURVIVAL; TOXICITY; ANIMAL; COLORECTAL NEOPLASMS; GENETIC EPIGENESIS; GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); EPIGENESIS, GENETIC; FLUOROURACIL; GENE FREQUENCY; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84928139184     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16048884     Document Type: Review

References (46)

1. Diaz-Rubio, E.; Tabernero, J.; Gomez-Espana, A.; Massutì, B.; Sastre, J.; Chaves, M.; Abad, A.; Carrato, A.; Queralt, B.; Reina, J.J.; et al. Spanish Cooperative Group for the Treatment of Digestive Tumor Trial. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J. Clin. Oncol. 2007, 25, 4224-4230.
2. Rich, T.A.; Shepard, R.C.; Mosley, S.T. Four decades of continuing innovation with fluorouracil: Current and future approaches to fluorouracil chemoradiation therapy. J. Clin. Oncol. 2004, 22, 2214-2232.
3. Spears, C.P.; Gustavsson B.G.; Mitchell, M.S.; Spicer, D.; Berne, M.; Bernstein, L.; Danenberg, P.V. Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. Cancer Res. 1984, 44, 4144-4150.
4. Humeniuk, R.; Menon, L.G.; Mishra, P.J.; Gorlick, R.; Sowers, R.; Rode, W.; Pizzorno G.; Cheng, Y.C.; Kemeny, N.; Bertino, J.R.; et al. Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol. Cancer Ther. 2009, 8, 1037-1044.
5. Sobrero, A.F.; Aschele, C.; Bertino, J.R. Fluorouracil in colorectal cancer-A tale of two drugs: Implications for biochemical modulation. J. Clin. Oncol. 1997, 15, 368-381.
6. Diasio, R.B.; Harris, B.E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 1989, 16, 215-237.
7. Wei, X.; Elizondo, G.; Sapone, A.; McLeod, H.L.; Raunio, H.; Fernandez-Salguero, P.; Gonzalez, F.J. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 1998, 51, 391-400.
8. Etienne, M.C.; Lagrange, J.L.; Dassonville, O.; Fleming, R.; Thyss, A.; Renée, N.; Schneider, M.; Demard, F.; Milano, G. Population study of dihydropyrimidine dehydrogenase in cancer-patients. J. Clin. Oncol. 1994, 12, 2248-2253.
9. Johnson, M.R.; Wang, K.; Diasio, R.B. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound hetreozigotegenotype. Clin. Cancer Res. 2002, 8, 768-774.
10. Caudle, K.E.; Thorn, C.F.; Klein, T.E.; Swen, J.J.; McLeod, H.L.; Diasio, R.B.; Schwab, M. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin. Pharmacol. Ther. 2013, 94, 640-645.
11. Van Kuilenburg, A.B.; Meinsma, R.; Zoetekouw, L.; van Gennip, A.H. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14+1G>A mutation. Int. J. Cancer 2002, 101, 253-258.
12. Van Kuilenburg, A.B.; Häusler, P.; Schalhorn, A.; Tanck, M.W.; Proost, J.H.; Terborg, C.; Behnke, D.; Schwabe, W.; Jabschinsky, K.; Maring, J.G. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy. Clin. Pharmacokinet. 2012, 51, 163-174.
13. Amstutz, U.; Froehlich, T.K.; Largiadèr, C.R. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 2011, 12, 1321-1336.
14. Maring, J.G.; van Kuilenburg, A.B.; Haasjes, J.; Piersma, H.; Groen, H.J.; Uges, D.R.; Gennip, A.H.; de Vries, E.G. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br. J. Cancer 2002, 86, 1028-1033.
15. Morel, A.; Boisdron-Celle, M.; Fey, L.; Soulie, P.; Craipeau, M.C.; Traore, S.; Gamelin, E. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol. Cancer Ther. 2006, 5, 2895-2904.
16. Ensembl. Available online: http://www.ensembl.org/index.html (accessed on 16 April 2015).
17. Lee, A.M.; Shi, Q.; Pavey, E.; Alberts S.R.; Sargent, D.J.; Sinicrope, F.A.; Berenberg, J.L.; Goldberg, R.M.; Diasio, R.B. DPYD Variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J. Natl. Cancer Inst. 2014, 106, doi:10.1093/jnci/dju298.
18. Rosmarin, D.; Palles, C.; Churc, D.; Domingo, E.; Jones, A.; Johnstone, E.; Wang, H.; Love, S.; Julier, P.; Scudder, C.; et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review and meta-analysis. J. Clin. Oncol. 2014, 32, 1031-1039.
19. Chansky, K.; Benedetti, J.; Macdonald, J.S. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 2005, 103, 1165-1171.
20. Offer, S.M.; Lee, A.M.; Mattison, L.K.; Fossum, C.; Wegner, N.J.; Diasio, R.B. A DPD variant (Y186C) in individuals of African ancestry is associated with reduced DPD enzyme activity. Clin. Pharmacol. Ther. 2013, 94, 158-166.
21. Van Kuilenburg, A.B.; Haasjes, J.; Richel, D.J.; Zoetekouw, L.; van Lenthe, H.; de Abreu, R.A.; Maring, J.G.; Vreken, P.; van Gennip, A.H. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene. Clin. Cancer Res. 2000, 6, 4705-4712.
22. Offer, S.M.; Fossum, C.C.; Wegner, N.J.; Stuflesser, A.J.; Butterfield, G.L.; Diasio, R.B. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res. 2014, 74, 2545-2554.
23. Gross, E.; Busse, B.; Riemenschneider, M.; Neubauer, S.; Seck, K.; Klein, H.G.; Kiechle, M.; Lordick, F.; Meindl, A. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLo S ONE 2008, 3, e4003.
24. Loganayagam, A.; Arenas Hernandez, M.; Corrigan, A.; Fairbanks, L.; Lewis, C.M.; Harper, P.; Maisey, N.; Ross, P.; Sanderson, J.D.; Marinaki, A.M. Pharmacogenetic variant in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br. J. Cancer 2013, 108, 2505-2515.
25. Schwab, M.; Zanger, U.M.; Marx, C.; Schaeffeler, E.; Klein, K.; Dippon, J.; Kerb, R.; Blievernicht, J.; Fischer, J.; Hofmann, U.; et al. German 5-FU Toxicity Study Group. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU Toxicity Study Group. J. Clin. Oncol. 2008, 26, 2131-2138.
26. Amstutz, U.; Farese, S.; Aebi, S.; Largiadèr, C.R. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: A haplotype assessment. Pharmacogenomics 2009, 10, 931-944.
27. Deenen, M.J.; Tol, J.; Burylo, A.M.; Doodeman, V.D.; de Boer, A.; Vincent, A.; Guchelaar, H.J.; Smits, P.H.; Beijnen, J.H.; Punt, C.J.; et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin. Cancer Res. 2011, 17, 3455-3468.
28. Kleibl, Z.; Fidlerova, J.; Kleiblova, P.; Kormunda, S.; Bilek, M.; Bouskova, K.; Sevcik, J.; Novotny, J. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma 2009, 56, 303-316.
29. Van Kuilenburg, A.B.; Meijer, J.; Mul, A.N.; Meinsma, R.; Schmid, V.; Dobritzsch, D.; Hennekam, R.C.; Mannens, M.M.; Kiechle, M.; Etienne-Grimaldi, M.C.; et al. Intragenic deletions and a deep intronic mutation affecting pre-m RNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum. Genet. 2010, 128, 529-538.
30. Froehlich, T.K.; Amstutz, U.; Aebi, S.; Joerger, M.; Largiadèr, C.R. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int. J. Cancer 2015, 136, 730-739.
31. Teh, L.K.; Hamzah, S.; Hashim, H.; Bannur, Z.; Zakaria, Z.A.; Hasbullani, Z.; Shia, J.K.; Fijeraid, H.; Md Nor, A.; Zailani, M.; et al. Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients. Ther. Drug Monit. 2013, 35, 625-630.
32. Falvella, F.S.; Cheli, S.; de Braud, F.; Clementi, E.; Pietrantonio, F. Predictive testing for DPD deficiency in a patient with familiar history of fluoropyrimidine-associated toxicity. Pers. Med. 2014, 11, 259-262.
33. Barbarino, J.M.; Haidar, C.E.; Klein, T.E.; Altman, R.B. Pharm GKB summary: Very important pharmacogene information for UGT1A1. Pharmacogenet. Genomics 2014, 24, 177-183.
34. Innocenti, F.; Schilsky, R.L.; Ramírez, J.; Janisch, L.; Undevia, S.; House, L.K.; Das, S.; Wu, K.; Turcich, M.; Marsh, R.; et al. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J. Clin. Oncol. 2014, 32, 2328-2334.
35. Falcone, A.; Ricci, S.; Brunetti, I.; Pfanner, E.; Allegrini, G.; Barbara, C.; Crinò, L.; Benedetti, G.; Evangelista, W.; Fanchini, L.; et al. Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucoverin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucoverin and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 2007, 25, 1670-1676.
36. Gruenberger, T.; Bridgewater, J.; Chau, I.; Alfonso, P.G.; Rivoire, M.; Mudan, S.; Lasserre, S.; Hermann, F.; Waterkamp, D.; Adam, R. Bevacizumab plus m FOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: The OLIVIA multinational randomized phase II trial. Ann. Oncol. 2015, 26, 702-708.
37. Loupakis, F.; Cremolini, C.; Salvatore, L.; Masi, G.; Sensi, E.; Schirripa, M.; Michelucci, A.; Pfanner, E.; Brunetti, I.; Lupi, C.; et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur. J. Cancer 2014, 50, 57-63.
38. Loupakis, F.; Cremolini, C.; Masi, G.; Lonardi, S.; Zagonel, V.; Salvatore, L.; Cortesi, E.; Tomasello, G.; Ronzoni, M.; Spadi, R.; et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N. Engl. J. Med. 2014, 371, 1609-1618.
39. Falvella, F.S.; Cheli, S.; Martinetti, A.; Mazzali, C.; Iacovelli, R.; Maggi, C.; Gariboldi, M.; Pierotti, M.A.; di Bartolomeo, M,.; Sottotetti, E.; et al. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. Br. J. Clin. Pharmacol. 2015, doi:10.1111/bcp.12631.
40. Noguchi, T.; Tanimoto, K.; Shimokuni, T.; Ukon, K.; Tsujimoto, H.; Fukushima, M.; Noguchi, T.; Kawahara, K.; Hiyama, K.; Nishiyama, M. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin. Cancer Res. 2004, 10, 7100-7107.
41. Ezzeldin, H.H.; Lee, A.M.; Mattison, L.K.; Diasio, R.B. Methylation of the DPYD promoter: An alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin. Cancer Res. 2005, 11, 8699-8705.
42. Savva-Bordalo, J.; Ramalho-Carvalho, J.; Pinheiro, M.; Costa, V.L.; Rodrigues, A.; Dias, P.C.; Veiga, I.; Machado, M.; Teixeira, M.R.; Henrique, R.; et al. Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients. BMC Cancer 2010, 10, 470.
43. Hirota, T.; Date, Y.; Nishibatake, Y.; Takane, H.; Fukuoka, Y.; Taniguchi, Y.; Burioka, N.; Shimizu, E.; Nakamura, H.; Otsubo, K.; et al. Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain micro RNAs in human lung tissues. Lung Cancer 2012, 77, 16-23.
44. Offer, S.M.; Butterfield, G.L.; Jerde, C.R.; Fossum, C.C.; Wegner, N.J.; Diasio, R.B. Micro RNAs mi R-27a and mi R-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. Mol. Cancer Ther. 2014, 13, 742-751.
45. Amstutz, U.; Offer, S.M.; Sistonen, J.; Joerger, M.; Diasio, R.B.; Largiadèr, R. Polymorphisms in MIR27A associated with early-onset toxicity in fluoropyrimidine-based chemotherapy. Clin. Cancer Res. 2015, doi:10.1158/1078-0432.CCR-14-2817.
46. Steiner, M.; Seule, M.; Steiner, B.; Bauer, I.; Freund, M.; Köhne, C.H.; Schuff-Werner, P. 5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: Report of a case. J. Clin. Pathol. 2005, 58, 553-555.